A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from working normally. This study focuses on NSCLC in later stages (advanced). This means that the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery (unresectable). People with unresectable, advanced or metastatic NSCLC often get treatment with immunotherapy and/or platinum-based chemotherapy (such as cisplatin or carboplatin). Immunotherapy helps the body's germ-fighting (immune) system fight cancer. Chemotherapy kills cancer cells or slows their growth. Over time, these treatments may stop working and the cancer can get worse. Researchers are looking for ways to make immunotherapy work better. One approach is to help the immune system recognize cancer more easily by activating certain cells, called T cells, to attack and kill the tumor cells. TAK-928 is designed to attach to T cells in the tumor and make them more active and abundant. This may help the body fight the cancer and destroy tumor cells. The main aim of this study is to learn how well TAK-928 works and compares with the usual treatment (also called standard of care), docetaxel, in adults with unresectable, advanced or metastatic NSCLC. Another aim is to learn how safe TAK-928 is in adults with NSCLC. The participants can be treated for up to 2 years (24 months) depending on how a participant responds, side effects, or other reasons. Researchers will check a participant's condition until the treatment is ended. During the study, participants will visit the study clinic several times.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Zaawansowany rak płuca typu płaskonabłonkowy, który nie da się operować lub rozprzestrzenił się na inne organy
- •Wcześniej otrzymywali leczenie immunoterapią i chemioterapią na bazie platyny, bez skutku
- •Chęć uczestnictwa i możliwość podpisania zgody na udział w badaniu
- •Zdolność do regularnego przybycia do kliniki badawczej
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (45)
St. Bernards Healthcare
Jonesboro, United States
Memorial Care
Fountain Valley, United States
Cancer and Blood Specialty Clinic
Los Alamitos, United States
Translation Research in Oncology- US, INC (TRIO-US)
Torrance, United States
D & H Cancer Research Center
Margate, United States
BRCR Global
Tamarac, United States
The University of Texas M.D Anderson Cancer Center (MDACC)
Houston, United States
The First Affiliated Hospital of Anhui Medical University
Hefei, China
Anhui Provincial Cancer Hospital
Hefei, China
Anhui Provincial Hospital
Hefei, China
Peking University People's Hospital
Beijing, China
Beijing Cancer Hospital
Beijing, China
Chongqing University Cancer Hospital
Chongqing, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
The Affiliated Hospital of Fujian Medical University
Fuzhou, China
Fujian Cancer Hospital
Fuzhou, China
Guangdong Provincial People's Hospital
Guangzhou, China
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Guangzhou, China
The Fourth Hospital of Hebei University
Shijiazhuang, China
Harbin Medical University Cancer Hospital
Harbin, China
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, China
Henan Cancer Hospital
Zhengzhou, China
Henan Provincial People's Hospital
Zhengzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
The Third Xiangya Hospital of Central South University
Changsha, China
Nanjing Drum Tower Hospital
Nanjing, China
Nanjing Drum Tower Hospital
Nanjing, China
Jiangsu Province Hospital
Nanjing, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
Liaoning Cancer Hospital
Shenyang, China
Shandong Cancer Hospital
Jinan, China
Shanghai Chest Hospital
Shanghai, China
Shanghai Pulmonary Hospital
Shanghai, China
The First Affiliated Hospital of Xi'An Jiaotong University
Xi'an, China
Sichuan Cancer Hospital
Chengdu, China
West China Hospital of Sichuan University
Chengdu, China
The Affiliated Hospital of Southwest Medical University
Luzhou, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Yunnan Cancer Hospital
Kunming, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
National Cancer Center
Tokyo, Japan
Trial contact
Takeda Contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.